VKTX
Viking Therapeutics, Inc. NASDAQ Listed Apr 28, 2015$31.59
Pre-mkt
$31.19
-0.43%
Mkt Cap $3.7B
52w Low $22.96
42.7% of range
52w High $43.15
50d MA $33.46
200d MA $32.76
P/E (TTM)
-9.4x
EV/EBITDA
-9.7x
P/B
5.3x
Debt/Equity
0.0x
ROE
-56.3%
P/FCF
-14.2x
RSI (14)
—
ATR (14)
—
Beta
0.82
50d MA
$33.46
200d MA
$32.76
Avg Volume
2.6M
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
9920 Pacific Heights Boulevard · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | -1.01 | -1.37 | -35.6% | 31.33 | -2.7% | -0.5% | -3.8% | +5.9% | -1.4% | +3.1% | — |
| Feb 11, 2026 | AMC | -0.89 | -1.38 | -55.1% | 28.55 | +18.2% | +6.8% | -4.9% | +5.0% | -1.0% | +3.2% | — |
| Oct 22, 2025 | AMC | -0.70 | -0.81 | -15.7% | 31.42 | +12.8% | +8.0% | +1.5% | +4.4% | -2.8% | +0.8% | — |
| Jul 23, 2025 | AMC | -0.44 | -0.58 | -31.8% | 33.40 | -5.7% | +0.3% | +2.7% | -3.5% | -0.9% | +2.4% | — |
| Apr 23, 2025 | AMC | -0.34 | -0.41 | -20.6% | 25.79 | +1.2% | -0.5% | -2.6% | +3.8% | +7.7% | +3.3% | — |
| Feb 5, 2025 | AMC | -0.28 | -0.32 | -14.3% | 33.50 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% | — |
| Oct 23, 2024 | AMC | -0.24 | -0.22 | +8.3% | 60.39 | +8.9% | +21.2% | +6.6% | -4.5% | -1.6% | -2.2% | — |
| Jul 24, 2024 | AMC | -0.26 | -0.20 | +23.1% | 50.41 | +17.0% | +28.3% | +2.0% | -7.2% | -7.7% | +0.8% | — |
| Apr 24, 2024 | AMC | -0.27 | -0.26 | +3.7% | 65.07 | -3.2% | +5.8% | +7.9% | +1.5% | +5.5% | -4.0% | — |
| Feb 7, 2024 | AMC | -0.25 | -0.25 | +0.0% | 24.48 | +5.2% | +18.0% | +5.8% | +3.8% | -3.6% | +5.3% | — |
| Oct 25, 2023 | AMC | -0.22 | -0.23 | -4.5% | 10.67 | -15.7% | -9.4% | -4.4% | +3.7% | +2.4% | -2.4% | — |
| Jul 26, 2023 | AMC | -0.21 | -0.19 | +9.5% | 14.28 | -4.7% | -4.0% | +5.3% | +0.4% | -2.3% | -1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.33 | $30.48 | -2.7% | -0.5% | -3.8% | +5.9% | -1.4% | +3.1% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.33 | $32.34 | +0.0% | +0.7% | -1.2% | +3.2% | +3.2% | -5.1% |
| Nov 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $40.60 | $42.22 | +4.0% | +0.4% | -4.4% | +0.3% | -2.3% | -1.2% |
| Oct 24 | JP Morgan | Maintains | Overweight → Overweight | — | $33.92 | $35.00 | +3.2% | +1.5% | +4.4% | -2.8% | +0.8% | +8.4% |
| Oct 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $31.42 | $35.44 | +12.8% | +8.0% | +1.5% | +4.4% | -2.8% | +0.8% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.57 | $25.55 | -0.1% | +0.9% | +1.8% | +4.1% | +1.9% | +6.6% |
| Sep 22 | BTIG | Maintains | Buy → Buy | — | $25.40 | $25.35 | -0.2% | +3.3% | -4.9% | +6.6% | -5.8% | +1.9% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.09 | $26.00 | -38.2% | -42.1% | +5.5% | -0.1% | +1.3% | -0.6% |
| Jul 24 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $33.40 | $31.50 | -5.7% | +0.3% | +2.7% | -3.5% | -0.9% | +2.4% |
| Jul 24 | Citigroup | Maintains | Neutral → Neutral | — | $33.40 | $31.50 | -5.7% | +0.3% | +2.7% | -3.5% | -0.9% | +2.4% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.95 | $27.11 | +0.6% | +0.5% | +4.0% | -5.9% | -0.1% | +0.6% |
| Apr 28 | Truist | Maintains | Buy → Buy | — | $24.99 | $25.11 | +0.5% | +3.8% | +7.7% | +3.3% | -0.9% | +2.6% |
| Apr 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.79 | $26.09 | +1.2% | -0.5% | -2.6% | +3.8% | +7.7% | +3.3% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.79 | $26.09 | +1.2% | -0.5% | -2.6% | +3.8% | +7.7% | +3.3% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.60 | $22.04 | -6.6% | +1.4% | -0.9% | +7.4% | +1.2% | -0.5% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.98 | $28.00 | +0.1% | -5.9% | -0.8% | -1.8% | -5.8% | -1.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.96 | $26.26 | -6.1% | -5.2% | +11.4% | +0.6% | +3.9% | -3.4% |
| Feb 7 | B. Riley Securities | Maintains | Buy → Buy | — | $31.46 | $31.40 | -0.2% | +3.5% | -7.3% | -0.7% | -2.1% | +0.6% |
| Feb 7 | Maxim Group | Maintains | Buy → Buy | — | $31.46 | $31.40 | -0.2% | +3.5% | -7.3% | -0.7% | -2.1% | +0.6% |
| Feb 6 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $33.50 | $31.02 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.50 | $31.02 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.50 | $31.02 | -7.4% | -6.1% | +3.5% | -7.3% | -0.7% | -2.1% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.56 | $32.94 | +1.2% | +0.3% | +0.7% | +3.6% | +2.6% | -1.3% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.60 | $40.00 | -1.5% | -3.2% | -1.1% | -12.7% | +2.7% | -6.6% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.66 | $41.52 | -0.3% | -2.5% | -3.2% | -1.1% | -12.7% | +2.7% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.49 | $44.18 | +6.5% | +1.8% | +0.2% | +0.1% | +0.8% | -3.6% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.70 | $43.09 | -7.7% | -18.0% | +8.4% | +1.8% | +0.2% | +0.1% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.42 | $53.33 | -0.2% | +2.0% | -2.9% | -2.7% | -2.4% | +1.9% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.99 | $55.27 | +6.3% | +2.8% | +2.0% | -2.9% | -2.7% | -2.4% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.14 | $63.53 | +0.6% | +2.4% | +1.9% | +4.5% | -0.5% | -8.0% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.39 | $65.75 | +8.9% | +21.2% | +6.6% | -4.5% | -1.6% | -2.2% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.68 | $67.16 | +0.7% | -6.1% | -0.3% | +5.4% | -0.1% | -0.6% |
| Sep 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $61.93 | $62.69 | +1.2% | +1.9% | -1.3% | -1.1% | +2.7% | -2.1% |
| Sep 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $60.83 | $62.71 | +3.1% | +3.3% | +6.2% | +0.6% | -6.2% | +2.4% |
| Jul 25 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $50.41 | $59.00 | +17.0% | +28.3% | +2.0% | -7.2% | -7.7% | +0.8% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.41 | $59.00 | +17.0% | +28.3% | +2.0% | -7.2% | -7.7% | +0.8% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.74 | $52.42 | -0.6% | -1.2% | -8.3% | -0.9% | +7.1% | +4.4% |
| Jun 17 | Truist | Maintains | Buy → Buy | — | $52.02 | $51.61 | -0.8% | +0.0% | -2.7% | -0.4% | +4.6% | -1.2% |
| Jun 4 | Maxim Group | Maintains | Buy → Buy | — | $62.27 | $65.00 | +4.4% | -9.7% | +4.7% | -6.6% | +1.8% | +0.7% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.27 | $65.00 | +4.4% | -9.7% | +4.7% | -6.6% | +1.8% | +0.7% |
| May 16 | Raymond James | Upgrade | Outperform → Strong Buy | — | $78.01 | $76.26 | -2.2% | -11.5% | -3.0% | +0.8% | -4.9% | -1.9% |
| May 16 | Truist | Maintains | Buy → Buy | — | $78.01 | $76.26 | -2.2% | -11.5% | -3.0% | +0.8% | -4.9% | -1.9% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.07 | $63.00 | -3.2% | +5.8% | +7.9% | +1.5% | +5.5% | -4.0% |
| Mar 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $80.83 | $82.08 | +1.5% | +3.1% | -1.6% | -3.0% | -2.7% | +1.4% |
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $69.19 | $77.51 | +12.0% | +16.8% | +3.1% | -1.6% | -3.0% | -2.7% |
| Mar 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $69.19 | $77.51 | +12.0% | +16.8% | +3.1% | -1.6% | -3.0% | -2.7% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.19 | $77.51 | +12.0% | +16.8% | +3.1% | -1.6% | -3.0% | -2.7% |
| Mar 15 | Stifel | Maintains | Buy → Buy | — | $65.05 | $67.20 | +3.3% | -3.8% | +1.3% | +2.9% | +9.0% | -0.6% |
| Mar 15 | Maxim Group | Maintains | Buy → Buy | — | $65.05 | $67.20 | +3.3% | -3.8% | +1.3% | +2.9% | +9.0% | -0.6% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.05 | $67.20 | +3.3% | -3.8% | +1.3% | +2.9% | +9.0% | -0.6% |
No insider trades available.
8-K · 1.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 1.02: Material Agreement Terminated
The TR-Beta Program license termination with Valley Blvd effective May 4, 2026 removes a development partnership, though the filing doesn't specify whether this was mutual, breach-based, or regulatory-driven—investors should clarify the reason's impact on the company's pipeline.
Apr 30
8-K
Viking Therapeutics, Inc -- 8-K Filing
Unable to provide analysis: this 8-K contains only signature blocks without disclosed material events, transactions, or financial information necessary for investor guidance.
Feb 11
Data updated apr 27, 2026 7:49am
· Source: massive.com